Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Riociguat (Adempas — Bayer HealthCare) indication: chronic thromboembolic pulmonary hypertension. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0353. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that riociguat be listed for the management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH, World Health Organization [WHO] Group 4) or persistent or recurrent CTEPH after surgical treatment in adult patients (≥ 18 years of age) with WHO Functional Class (FC) II or III pulmonary hypertension (PH), if conditions are met. Indexing Status Subject indexing assigned by CRD MeSH Canada; Chronic Disease; Drug Evaluation; Familial Primary Pulmonary Hypertensions; Hypertension, Pulmonary; Molecular Targeted Therapy; Pulmonary Embolism; Pyrazoles; Pyrimidines; Treatment Outcome Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000180 Date abstract record published 04/03/2015 |
